New obesity drug shows promise in early trial
NCT ID NCT07431086
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new drug, olatorepatide, for weight loss in people who are overweight or obese but do not have diabetes. The drug works by targeting hormones that control appetite and blood sugar. Researchers will check how safe the drug is, how the body processes it, and how much weight participants lose compared to those taking a placebo.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVERWEIGHT OR OBESITY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Clinical Site Partners, LLC DBA Flourish Research
Winter Park, Florida, 32789, United States
-
Diablo Clinical Research - Flourish Research
Walnut Creek, California, 94598, United States
-
Flourish Research - San Antonio Medical Trials
San Antonio, Texas, 78229, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new injection help tackle obesity and diabetes? a safety trial begins
- Can a single injection of SYH2082 help tackle obesity? a first-in-human trial puts safety to the test.
- App sends mindfulness exercises right after weight regain to keep dieters on track
- Sleep program aims to reduce pregnancy risks in african american women
- Could a Muscle-Building drug boost weight loss? new trial tests bimagrumab with semaglutide
- Weekly shot could help shed pounds in obesity trial